Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mega Genomics Limited ( (HK:6667) ) has issued an update.
Mega Genomics Limited has called its annual general meeting for 21 May 2026 in Beijing to present the audited consolidated financial statements and the reports of directors and auditors for the year ended 31 December 2025. Shareholders will vote on the re-election of four directors, authorization for the board to set directors’ pay, and the reappointment and remuneration of Crowe (HK) CPA Limited as auditor.
The company will also seek shareholder approval for a final dividend of RMB0.15 per share for 2025, signaling a return of profits to investors. In addition, the board is asking for a general mandate to repurchase up to 10% of the company’s issued shares, which could provide flexibility in capital management and potentially support the share price, subject to Hong Kong listing rules and applicable laws.
More about Mega Genomics Limited
Mega Genomics Limited is a Cayman Islands-incorporated company listed in Hong Kong, operating in the genomics and life sciences sector. The company focuses on providing genetic testing and related health services, with core operations and corporate functions based in Beijing, positioning it to serve the mainland China healthcare and biotechnology market.
Average Trading Volume: 7,078
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$1.57B
See more insights into 6667 stock on TipRanks’ Stock Analysis page.